PCT

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Tohru TANAKA, et al.

Appln. No.: 09/445,963

Filed: December 16, 1999

Group Art Unit: 1614

Examiner: Not Yet Assigned

For: AGENT FOR DIAGNOSING AND TREATING MALIGNANT TUMORS

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction(s):

Title [DIAGNOSTIC AGENTS AND REMEDIES FOR MALIGNANT TUMORS] <u>AGENT</u> FOR DIAGNOSING AND TREATING MALIGNANT TUMORS

Verification for the requested correction is indicated on the original Declaration and Power of Attorney filed December 16, 1999.

This error was caused by the PTO and therefore no fee is necessary.

Respectfully submitted,

SUGHRUE, MION, ZINN,

MACPEAK & SEAS, PLLC 2100 Pennsylvania Avenue, N.W. Washington, D.C. 20037-3213

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

Date: May 18, 2000

Mark Boland

Registration No. 32,197

FILING RECEIPT OC000000004981502*



UNITED STATES DEPARTMENT OF COMMERCE Pat nt and Trad mark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS

Washington, D.C. 20231

GRP ART TOT APPLICATION NUMBER FILING DATE FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** IND CLAIMS UNIT CLAIMS 09/445,963 12/16/1999 918 1614 Q57226 1 4

MXB/VERONIC

SUGHRUE MION ZINN MACPEAK & SEAS 2100 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20037

Date Mailed: 03/03/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

TOHRU TANAKA, SAITAMA, JAPAN; 'HIROSHI SASAKI, TOKYO, JAPAN;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/JP98/02648 06/16/1998

Foreign Applications

JAPAN P.HEI.9-160945 06/18/1997 ~

Foreign filing license granted on 03/03/2000

Title

DIAGNOSTIC AGENTS AND REMEDIES FOR MALIGNANT TUMORS

AGENT FOR DIAGNOSING AND TREATING

Preliminary Class MALIGNANT TUMORS

514

Data entry by: BARRETO, NGA

Team: OIPE

Date: 03/03/2000

I IDDIDDI KKI DIBID DITOK KONI KODII BOKIO BOKIO BOKI BIDOK BIKA DIKA DIKA BILAR KKII BOKI BOKII BOKIO BIKIL BOKI BOKI BOKI BOKI BOKI BOKI

1 of 2

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- · The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- · The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231